Quotient Limited (NASDAQ:QTNT) insider D J. Paul E. Cowan sold 54,460 shares of the stock in a transaction dated Thursday, August 17th. The stock was sold at an average price of $4.06, for a total transaction of $221,107.60. Following the completion of the sale, the insider now directly owns 26,666 shares in the company, valued at approximately $108,263.96. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Quotient Limited (NASDAQ QTNT) traded down 2.01% during trading on Thursday, reaching $3.91. 142,115 shares of the company’s stock traded hands. Quotient Limited has a 12 month low of $3.75 and a 12 month high of $8.64. The company’s market capitalization is $56.21 million. The firm’s 50 day moving average is $5.92 and its 200-day moving average is $6.61.

Quotient Limited (NASDAQ:QTNT) last issued its earnings results on Monday, August 7th. The company reported ($0.55) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.55). Quotient Limited had a negative net margin of 381.66% and a negative return on equity of 13,050.41%. The company had revenue of $6.83 million for the quarter, compared to the consensus estimate of $5.70 million. Analysts expect that Quotient Limited will post ($2.09) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was first reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/08/17/quotient-limited-qtnt-insider-sells-221107-60-in-stock.html.

Several large investors have recently modified their holdings of QTNT. New York State Common Retirement Fund purchased a new stake in shares of Quotient Limited during the second quarter valued at approximately $101,000. Goldman Sachs Group Inc. acquired a new position in Quotient Limited during the second quarter worth about $104,000. Nationwide Fund Advisors acquired a new position in Quotient Limited during the second quarter worth about $111,000. Birchview Capital LP boosted its position in Quotient Limited by 36.9% in the second quarter. Birchview Capital LP now owns 79,700 shares of the company’s stock worth $587,000 after buying an additional 21,500 shares in the last quarter. Finally, Nicholas Hoffman & Company LLC. acquired a new position in Quotient Limited during the first quarter worth about $150,000. Institutional investors own 38.97% of the company’s stock.

A number of research firms recently weighed in on QTNT. Zacks Investment Research raised shares of Quotient Limited from a “sell” rating to a “hold” rating in a report on Wednesday, May 17th. ValuEngine raised shares of Quotient Limited from a “strong sell” rating to a “sell” rating in a report on Friday, June 30th.

Quotient Limited Company Profile

Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market.

Receive News & Ratings for Quotient Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient Limited and related companies with MarketBeat.com's FREE daily email newsletter.